One drug, 166 patents and $208-billion sales
Down To Earth|March 01, 2023
Arthritis drug Humira is a stark example of how the US patent regime allows drug firms to drain patients and the health system
One drug, 166 patents and $208-billion sales

ONE'S HEART bleeds for American patients. They pay the most for prescription drugs compared to all other jurisdictions despite many ironies: a very large number of life-saving drugs are discovered by public-funded research in US universities and institutions; these pharmaceuticals are made in the US and by leading US-based manufacturers. Why is this so? It is because of a clutch of related reasons starting with the fact that there is no regulation of drug prices by the government but most of all, from exploiting a patent system that allows pharma companies to keep out competition and keep prices sky high. That's the root of the problem.

A case study of how drug companies manipulate the patent regime is AbbVie with its blockbuster anti-inflammation and arthritis drug Humira. The pharma giant has created a patent thicket around this top-selling biological medicine, by applying for an incredible 312 patents on this single drug and obtaining 166! And most of these patents (94 per cent) were sought after the drug was approved by the authorities. This has allowed AbbVie to garner revenues of US $208 billion since the patent was first granted in 2002. But here's the most disturbing aspect of Humira: two-thirds of this revenue was earned after its primary patents expired in 2016.

That was when patients and health insurance companies that pick up the tab for the drug were hoping to benefit from the less expensive biosimilar versions of the drug that were all set to launch in the US. But it did not happen. By shrewdly exploiting the US patent system, AbbVie blocked competitors from entering the market by using lawsuits against potential competitors and forcing them to accept settlements to delay their entry till 2023. The first of the biosimilar versions of Humira has only now been launched in the US, in February 2023-almost seven years after patent expiry.

This story is from the March 01, 2023 edition of Down To Earth.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the March 01, 2023 edition of Down To Earth.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM DOWN TO EARTHView All
In leading role again
Down To Earth

In leading role again

MOVIES AND WEB SERIES ARE ONCE AGAIN BEING SET IN RUSTIC BACKGROUNDS, INDICATING A RECONNECT BETWEEN CINEMA AND THE COUNTRYSIDE

time-read
5 mins  |
December 16, 2024
One Nation One Subscription comes at a huge cost
Down To Earth

One Nation One Subscription comes at a huge cost

As top US universities scrap big deals with top scientific publishers, India’s ONOS scheme seems flawed and outdated

time-read
4 mins  |
December 16, 2024
Return of Rambhog
Down To Earth

Return of Rambhog

Bid to revive and sell the aromatic indigenous paddy variety has led to substantial profits for farmers in Uttar Pradesh's Terai region

time-read
4 mins  |
December 16, 2024
Scarred by mining
Down To Earth

Scarred by mining

Natural springs of Kashmir drying up due to illegal riverbed mining

time-read
5 mins  |
December 16, 2024
Human-to-human spread a mutation away
Down To Earth

Human-to-human spread a mutation away

CANADA IN mid-November confirmed its first human case of avian influenza, with a teenager in the British Columbia being hospitalised after contracting the H5N1 virus that causes the disease. The patient developed a severe form of the disease, also called bird flu, and had respiratory issues. There was no known cause of transmission.

time-read
1 min  |
December 16, 2024
True rehabilitation
Down To Earth

True rehabilitation

Residents of Madhya Pradesh's Kakdi village take relocation as an opportunity to undertake afforestation, develop sustainable practices

time-read
2 mins  |
December 16, 2024
INESCAPABLE THREAT
Down To Earth

INESCAPABLE THREAT

Chemical pollution is the most underrated and underreported risk of the 21st century that threatens all species and regions

time-read
10+ mins  |
December 16, 2024
THAT NIGHT, 40 YEARS AGO
Down To Earth

THAT NIGHT, 40 YEARS AGO

Bhopal gas disaster is a tragedy that people continue to face

time-read
8 mins  |
December 16, 2024
A JOKE, INDEED
Down To Earth

A JOKE, INDEED

A CONFERENCE OF IRRESPONSIBLE PARTIES THAT CREATED AN OPTICAL ILLUSION TO THE REALITY OF A NEW CLIMATE

time-read
10+ mins  |
December 01, 2024
THINGS FALL APART
Down To Earth

THINGS FALL APART

THE WORLD HAS MADE PROGRESS IN MITIGATING EMISSIONS AND ADAPTING TO CLIMATE IMPACTS. BUT THE PROGRESS REMAINS GROSSLY INADEQUATE

time-read
4 mins  |
December 01, 2024